Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
HUTCHMED (China) Limited - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
HCM
Nasdaq
2830
www.hutch-med.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for HUTCHMED (China) Limited
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
- Jan 13th, 2026 9:00 pm
Wall Street Analysts Predict a 55.93% Upside in HUTCHMED (HCM): Here's What You Should Know
- Jan 7th, 2026 7:55 am
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
- Jan 6th, 2026 5:00 pm
HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma
- Jan 4th, 2026 5:00 pm
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification
- Dec 30th, 2025 3:00 am
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma
- Dec 29th, 2025 1:35 am
HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors
- Dec 16th, 2025 5:00 pm
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China
- Dec 7th, 2025 5:00 pm
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
- Nov 26th, 2025 5:00 pm
Private equity firms among HUTCHMED (China) Limited's (LON:HCM) largest stockholders and were hit after last week's 4.8% price drop
- Nov 23rd, 2025 12:15 am
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
- Nov 5th, 2025 6:35 am
HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO®
- Nov 4th, 2025 5:00 pm
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event
- Nov 2nd, 2025 5:00 pm
CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
- Oct 31st, 2025 6:35 am
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
- Oct 30th, 2025 6:00 pm
HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Oct 22nd, 2025 6:00 pm
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
- Oct 14th, 2025 2:30 am
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress
- Oct 12th, 2025 10:00 pm
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025
- Oct 1st, 2025 6:00 pm
HUTCHMED (China) (LON:HCM) shareholder returns have been respectable, earning 63% in 3 years
- Sep 19th, 2025 12:01 am
Scroll